Clinical Trial

Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain

Study acronym: HA35-HZ
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2026 (before its estimated June 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-28.
Trial Details
NCT Number NCT07569978
Lead Sponsor Nakhia Impex LLC
Conditions Herpes Zoster, Zoster-Associated Pain, Postherpetic Neuralgia, Neuropathic Pain, Acute Pain
Enrollment 30 participants
Start Date 2026-05-01
Primary Completion 2026-06-10 (estimated)
Study Completion 2026-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-08